Staar Surg Financials
This page shows Staar Surg (STAA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High gross margins no longer protect STAA because operating overhead and working-capital drag now absorb the value created.
From FY2023 to FY2026, gross margin barely moved, but operating margin swung from8.7% to-38.3% . The missing bridge is overhead: in FY2026, SG&A plus R&D reached$314M against only$182M of gross profit, meaning the collapse came from the operating structure above the gross line rather than from the product suddenly becoming low-margin.
Cash burn is now an operating issue, not a buildout issue: FY2026 operating cash flow was
Liquidity still looks self-funded rather than lender-funded: cash at
Financial Health Signals
Based on FY2026 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Staar Surg's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Staar Surg has an operating margin of -38.3%, meaning the company retains $-38 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -4.0% the prior year.
Staar Surg's revenue declined 23.7% year-over-year, from $313.9M to $239.4M. This contraction results in a growth score of 10/100.
Staar Surg carries a low D/E ratio of 0.28, meaning only $0.28 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 5.12, Staar Surg holds $5.12 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Staar Surg generated -$34.2M in operating cash flow, capex of $5.8M consumed most of it, leaving -$40.0M in free cash flow. This results in a low score of 2/100, reflecting heavy capital investment rather than weak cash generation.
Staar Surg generates a -22.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -5.1% the prior year.
Staar Surg passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Staar Surg generates $0.43 in operating cash flow (-$34.2M OCF vs -$80.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Staar Surg generated $239.4M in revenue in fiscal year 2026. This represents a decrease of 23.7% from the prior year.
Staar Surg's EBITDA was -$83.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1396.4% from the prior year.
Staar Surg reported -$80.4M in net income in fiscal year 2026. This represents a decrease of 298.1% from the prior year.
Staar Surg earned $-1.62 per diluted share (EPS) in fiscal year 2026. This represents a decrease of 295.1% from the prior year.
Cash & Balance Sheet
Staar Surg generated -$40.0M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 422.2% from the prior year.
Staar Surg held $131.9M in cash against $0 in long-term debt as of fiscal year 2026.
Staar Surg had 50M shares outstanding in fiscal year 2026. This represents an increase of 0.4% from the prior year.
Margins & Returns
Staar Surg's gross margin was 76.2% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.
Staar Surg's operating margin was -38.3% in fiscal year 2026, reflecting core business profitability. This is down 34.3 percentage points from the prior year.
Staar Surg's net profit margin was -33.6% in fiscal year 2026, showing the share of revenue converted to profit. This is down 27.2 percentage points from the prior year.
Staar Surg's ROE was -22.8% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 17.7 percentage points from the prior year.
Capital Allocation
Staar Surg invested $40.1M in research and development in fiscal year 2026. This represents a decrease of 11.6% from the prior year.
Staar Surg spent $6.5M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding.
Staar Surg invested $5.8M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 75.1% from the prior year.
STAA Income Statement
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $93.5M+61.8% | $57.8M-39.0% | $94.7M+113.7% | $44.3M+4.1% | $42.6M-13.0% | $49.0M-44.7% | $88.6M-10.5% | $99.0M |
| Cost of Revenue | $24.7M+75.4% | $14.1M-16.6% | $16.9M+46.3% | $11.5M-21.0% | $14.6M-15.7% | $17.3M-13.9% | $20.1M-2.4% | $20.6M |
| Gross Profit | $68.9M+57.4% | $43.7M-43.8% | $77.9M+137.4% | $32.8M+17.1% | $28.0M-11.5% | $31.6M-53.8% | $68.5M-12.7% | $78.4M |
| R&D Expenses | $9.9M+7.4% | $9.2M+0.4% | $9.2M-10.3% | $10.3M-9.5% | $11.3M+45.0% | $7.8M-36.1% | $12.2M+3.2% | $11.9M |
| SG&A Expenses | $60.9M-8.6% | $66.6M+12.1% | $59.4M-5.4% | $62.8M-26.5% | $85.4M+43.4% | $59.6M-5.2% | $62.8M-5.6% | $66.5M |
| Operating Income | $8.0M+134.9% | -$22.8M-223.5% | $18.5M+161.7% | -$30.0M+47.8% | -$57.4M-105.7% | -$27.9M-591.2% | $5.7M-52.2% | $11.9M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $3.0M+228.6% | -$2.3M-123.7% | $9.9M+208.8% | -$9.1M-3210.2% | -$275K-107.1% | $3.9M+22.5% | $3.2M+7.6% | $3.0M |
| Net Income | $5.2M+128.4% | -$18.3M-306.1% | $8.9M+152.8% | -$16.8M+69.0% | -$54.2M-58.4% | -$34.2M-443.0% | $10.0M+35.2% | $7.4M |
| EPS (Diluted) | $0.10 | N/A | $0.18+152.9% | $-0.34+69.1% | $-1.10 | N/A | $0.20+33.3% | $0.15 |
STAA Balance Sheet
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $451.1M-0.1% | $451.7M-1.0% | $456.4M+4.2% | $437.8M-4.3% | $457.4M-10.2% | $509.5M-5.2% | $537.6M+4.8% | $512.7M |
| Current Assets | $312.4M+0.3% | $311.5M-3.0% | $321.2M+9.7% | $292.8M-10.3% | $326.5M-11.3% | $367.9M-7.3% | $397.1M+3.5% | $383.8M |
| Cash & Equivalents | $131.9M-13.9% | $153.2M-13.1% | $176.2M+5.4% | $167.1M-3.5% | $173.1M+20.1% | $144.2M-12.1% | $164.0M-14.9% | $192.8M |
| Inventory | $35.0M-11.8% | $39.7M+13.7% | $34.9M+1.5% | $34.4M+14.5% | $30.0M+12.4% | $26.7M+11.8% | $23.9M-4.5% | $25.0M |
| Accounts Receivable | $81.2M+62.1% | $50.1M-16.7% | $60.1M+74.5% | $34.4M-13.8% | $39.9M-48.7% | $77.9M-25.5% | $104.5M+11.4% | $93.8M |
| Goodwill | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M0.0% | $1.8M |
| Total Liabilities | $98.8M-8.1% | $107.5M+4.8% | $102.6M+1.4% | $101.2M-5.8% | $107.4M-4.3% | $112.2M+2.5% | $109.5M+5.6% | $103.6M |
| Current Liabilities | $61.0M-11.0% | $68.5M+11.1% | $61.6M+4.1% | $59.2M-13.4% | $68.4M-2.8% | $70.3M+6.0% | $66.3M+0.3% | $66.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $352.4M+2.4% | $344.2M-2.7% | $353.8M+5.1% | $336.6M-3.8% | $350.0M-11.9% | $397.3M-7.2% | $428.1M+4.6% | $409.1M |
| Retained Earnings | -$142.8M+3.5% | -$148.0M-14.1% | -$129.7M+6.4% | -$138.6M-13.8% | -$121.8M-80.2% | -$67.6M-102.6% | -$33.3M+23.0% | -$43.3M |
STAA Cash Flow Statement
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.7M-454.3% | -$3.9M-246.8% | $2.7M+109.8% | -$27.2M-375.2% | -$5.7M-993.1% | $642K-83.2% | $3.8M+136.6% | -$10.4M |
| Capital Expenditures | $443K-73.6% | $1.7M+89.9% | $883K-50.7% | $1.8M+22.1% | $1.5M-74.4% | $5.7M-8.1% | $6.2M-0.1% | $6.2M |
| Free Cash Flow | -$22.1M-296.0% | -$5.6M-413.4% | $1.8M+106.1% | -$29.0M-303.2% | -$7.2M-41.7% | -$5.1M-110.5% | -$2.4M+85.5% | -$16.6M |
| Investing Cash Flow | $2.1M+111.1% | -$19.4M-467.5% | $5.3M-79.0% | $25.1M-28.9% | $35.4M+281.3% | -$19.5M+44.7% | -$35.2M-70.5% | -$20.7M |
| Financing Cash Flow | -$1.7M-3286.0% | -$50K-105.1% | $983K+121.7% | -$4.5M-378.9% | -$948K-761.8% | -$110K-106.8% | $1.6M+890.8% | $163K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $0-100.0% | $2.0M | N/A | N/A | N/A | N/A | N/A |
STAA Financial Ratios
| Metric | Q1'27 | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 73.6%-2.1pp | 75.7%-6.5pp | 82.2%+8.2pp | 74.0%+8.2pp | 65.8%+1.1pp | 64.6%-12.7pp | 77.3%-1.9pp | 79.2% |
| Operating Margin | 8.5%+48.0pp | -39.5%-59.0pp | 19.5%+87.1pp | -67.6%+67.2pp | -134.8%-77.8pp | -57.0%-63.4pp | 6.4%-5.6pp | 12.0% |
| Net Margin | 5.6%+37.3pp | -31.7%-41.1pp | 9.4%+47.3pp | -37.9%+89.4pp | -127.3%-57.4pp | -69.9%-81.2pp | 11.3%+3.8pp | 7.4% |
| Return on Equity | 1.5%+6.8pp | -5.3%-7.8pp | 2.5%+7.5pp | -5.0%+10.5pp | -15.5%-6.9pp | -8.6%-10.9pp | 2.3%+0.5pp | 1.8% |
| Return on Assets | 1.1%+5.2pp | -4.0%-6.0pp | 1.9%+5.8pp | -3.8%+8.0pp | -11.8%-5.1pp | -6.7%-8.6pp | 1.9%+0.4pp | 1.4% |
| Current Ratio | 5.12+0.6 | 4.55-0.7 | 5.21+0.3 | 4.94+0.2 | 4.78-0.5 | 5.23-0.8 | 5.99+0.2 | 5.80 |
| Debt-to-Equity | 0.28-0.0 | 0.31+0.0 | 0.29-0.0 | 0.300.0 | 0.31+0.0 | 0.28+0.0 | 0.260.0 | 0.25 |
| FCF Margin | -23.7%-14.0pp | -9.7%-11.5pp | 1.9%+67.4pp | -65.5%-48.6pp | -16.9%-6.5pp | -10.4%-7.6pp | -2.7%+14.1pp | -16.8% |
Similar Companies
Frequently Asked Questions
What is Staar Surg's annual revenue?
Staar Surg (STAA) reported $239.4M in total revenue for fiscal year 2026. This represents a -23.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Staar Surg's revenue growing?
Staar Surg (STAA) revenue declined by 23.7% year-over-year, from $313.9M to $239.4M in fiscal year 2026.
Is Staar Surg profitable?
No, Staar Surg (STAA) reported a net income of -$80.4M in fiscal year 2026, with a net profit margin of -33.6%.
What is Staar Surg's EBITDA?
Staar Surg (STAA) had EBITDA of -$83.4M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Staar Surg's gross margin?
Staar Surg (STAA) had a gross margin of 76.2% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Staar Surg's operating margin?
Staar Surg (STAA) had an operating margin of -38.3% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Staar Surg's net profit margin?
Staar Surg (STAA) had a net profit margin of -33.6% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Staar Surg's return on equity (ROE)?
Staar Surg (STAA) has a return on equity of -22.8% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Staar Surg's free cash flow?
Staar Surg (STAA) generated -$40.0M in free cash flow during fiscal year 2026. This represents a -422.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Staar Surg's operating cash flow?
Staar Surg (STAA) generated -$34.2M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Staar Surg's total assets?
Staar Surg (STAA) had $451.1M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Staar Surg's capital expenditures?
Staar Surg (STAA) invested $5.8M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Staar Surg spend on research and development?
Staar Surg (STAA) invested $40.1M in research and development during fiscal year 2026.
What is Staar Surg's current ratio?
Staar Surg (STAA) had a current ratio of 5.12 as of fiscal year 2026, which is generally considered healthy.
What is Staar Surg's debt-to-equity ratio?
Staar Surg (STAA) had a debt-to-equity ratio of 0.28 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Staar Surg's return on assets (ROA)?
Staar Surg (STAA) had a return on assets of -17.8% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Staar Surg's cash runway?
Based on fiscal year 2026 data, Staar Surg (STAA) had $131.9M in cash against an annual operating cash burn of $34.2M. This gives an estimated cash runway of approximately 46 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Staar Surg's Piotroski F-Score?
Staar Surg (STAA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Staar Surg's earnings high quality?
Staar Surg (STAA) has an earnings quality ratio of 0.43x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Staar Surg?
Staar Surg (STAA) scores 35 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.